Cellectis (the Company) (Euronext Growth ALCLS - NASDAQ CLLS) will present its first research data on the development of a novel universal CAR T-cell at the American Society of Cell and Gene Therapy Annual Meeting (ASGCT) being held on May 16-19, 2022. Cellectis novel immune-evasive CAR T -cell was developed using a combination of TALEN-mediated gene editing and adeno-associated virus (AAV) dependent gene insertion.
💼 Business Developments:
No specific business developments reported in this filing.
📞 Contact Information:
Media Contact: s: Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
🌍 Cellectis (CLLS) - Form 6-K Filing
Filing Date: 2022-05-16
Accepted: 2022-05-16 08:15:09
Event Type: Other Event
Event Details:
💼 Business Developments:
No specific business developments reported in this filing.
📞 Contact Information: